Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | CFB | P00751 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478770 | 0.91 | KDM4A (0.34) | OPRK1CFB | |
| SCHEMBL2476738 | 0.88 | SMN1; SMN2 (0.36) | OPRK1HSP90AA1HSP90AB1 | |
| SCHEMBL2473409 | 0.86 | OPRK1 (0.38) | OPRK1OPRM1KCNH2OPRD1CFB | |
| SCHEMBL2473301 | 0.84 | AXL (0.33) | CFBABL1 | |
| SCHEMBL2475607 | 0.84 | KLKB1 (0.31) | — | |
| SCHEMBL2470023 | 0.84 | KLKB1 (0.31) | — | |
| SCHEMBL2470276 | 0.81 | AR (0.37) | — | |
| SCHEMBL2476471 | 0.81 | AR (0.37) | — | |
| SCHEMBL2472923 | 0.80 | OPRK1 (0.35) | OPRK1OPRM1KCNH2OPRD1HSP90AA1 | |
| SCHEMBL8300504 | 0.78 | OPRK1 (0.39) | OPRK1OPRM1KCNH2OPRD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | OPRK1 106/4885OPRM1 216/4885KCNH2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.